© 2021 MJH Life Sciences and HCPLive - Clinical news for connected physicians. All rights reserved.
© 2021 MJH Life Sciences™ and HCPLive - Clinical news for connected physicians. All rights reserved.
February 07, 2019
A novel bioequivalent of dimethyl fumarate (Tecfidera) may soon be offering another treatment option for patients with multiple sclerosis.
January 24, 2019
For patients in the HSCT group, disease-modifying therapies use was discontinued, followed by variable washout periods before admission for HSCT.
January 21, 2019
Acrolein levels were significantly elevated in urine and serum in patients with multiple sclerosis compared to healthy controls.
January 17, 2019
Ocrelizumab demonstrated superiority to or comparability with 14 other disease-modifying therapies currently approved by the European Medicines Agency.